Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

Lead Sponsor:

Roswell Park Cancer Institute

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumo...

Detailed Description

OBJECTIVES: Primary * Determine the maximum tolerated dose of capecitabine when given in combination with oxaliplatin and gefitinib in patients with metastatic colorectal cancer. (phase I) * Determi...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically or cytologically confirmed\* colorectal cancer
  • Metastatic disease
  • The site of the primary tumor must have been confirmed endoscopically, radiologically, or surgically to be the colon or rectum NOTE: \*Confirmation is not required for recurrent metastatic disease unless an interval of \> 5 years has elapsed between the initial primary surgery and the development of metastases
  • Measurable disease
  • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • No CNS metastases
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 to 80
  • Performance status
  • ECOG 0-1
  • Life expectancy
  • More than 3 months
  • Hematopoietic
  • Absolute neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Hemoglobin ≥ 9 g/dL (transfusion allowed)
  • Hepatic
  • AST and ALT ≤ 3 times upper limit of normal (ULN)
  • Bilirubin ≤ ULN
  • No unstable or uncompensated hepatic disease
  • Renal
  • Creatinine \< 1.5 times ULN OR
  • Creatinine clearance \> 60 mL/min
  • No unstable or uncompensated renal disease
  • Cardiovascular
  • No unstable or uncompensated cardiac disease
  • Pulmonary
  • No evidence of clinically active interstitial lung disease
  • Asymptomatic patients with chronic stable radiographic changes are eligible
  • No unstable or uncompensated respiratory disease
  • Other
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • No known hypersensitivity to gefitinib or any of its excipients
  • No known hypersensitivity to platinum compounds, fluorouracil, or capecitabine
  • No severe or uncontrolled systemic disease
  • Able to receive oral medication
  • No known dihydropyrimidine dehydrogenase (DPD) deficiency
  • No known peripheral neuropathy ≥ grade 1
  • Absence of deep tendon reflexes as the sole neurological abnormality allowed
  • No other significant clinical disorder or laboratory finding that would preclude study participation
  • No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix (phase II only)
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • At least 4 weeks since prior chemotherapy for metastatic colorectal cancer (phase I)
  • No prior chemotherapy for metastatic disease (phase II)
  • Prior fluorouracil and leucovorin calcium in the adjuvant setting allowed provided the last treatment was administered more than 6 months before the development of metastatic disease
  • No prior irinotecan and oxaliplatin (phase II)
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • No concurrent radiotherapy for colorectal cancer
  • Surgery
  • See Disease Characteristics
  • More than 4 weeks since prior major surgery (e.g., laparotomy)
  • Other
  • Recovered from all prior therapy (no unresolved chronic toxicity \> grade 2)
  • More than 4 weeks since prior investigational drugs
  • No prior epidermal growth factor receptor inhibitor therapy (phase II)
  • No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or Hypericum perforatum (St. John's wort)
  • No other concurrent investigational drugs
  • No other concurrent systemic therapy for colorectal cancer

Exclusion

    Key Trial Info

    Start Date :

    January 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT00087334

    Start Date

    January 1 2004

    Last Update

    February 1 2013

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Roswell Park Cancer Institute

    Buffalo, New York, United States, 14263-0001